Bridge Biotherapeutics : Material Management Information related to Judgment of Investment (US FDA approval of BBT-877 phase 2 clinical trial plan for the treatment of Idiopathic Pulmonary Fibrosis (IPF))
※ Investor NotesThe probability that a drug in clinical trial stage will become approved is known to be about 10%, statistically. In the process of...

